Display Settings:

Format

Send to:

Choose Destination
    Sci Transl Med. 2009 Dec 9;1(10):10ps11.

    Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.

    Source

    Amgen, Thousand Oaks, CA 91320, USA. public@robertsikorski.com

    Abstract

    It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.

    PMID:
    20368158
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk